Sourcing Exosomes in Indiana
Licensed Indiana practices order Kimera exosome material from ExaVeyra for topical aesthetic use, shipped frozen from Florida with a Certificate of Analysis and lot traceability on every vial. Indiana buyers need their own professional license and NPI; the wholesale drug distributor license is the supplier’s obligation, not the purchaser’s.
Indiana is stricter than most states about who may hold that supplier-side license. IC 25-26-14 requires wholesale distributors of legend drugs to maintain accreditation from the National Association of Boards of Pharmacy alongside Board of Pharmacy licensure, which puts a third-party audit behind every licensed distributor shipping into the state.
At a glance
| Question | Answer |
|---|---|
| Does ExaVeyra ship to Indiana? | Yes. Shipped frozen from Florida, as we do to all 50 states |
| Cold-chain shipping from Florida | Overnight shipping; arrival can take 1 to 3 business days |
| State regenerative-medicine statute | None |
| Does that statute reach exosomes? | No. Its definition is written around cells; exosomes are acellular and governed federally |
| Physician delegation required to hand off medical acts | Yes |
| Who holds the licensure to ship into the state | The pharmacy partner and the tissue bank that ship, not the purchasing practice |
| What ExaVeyra supplies here | Kimera exosome material; compounded preparations available through the 503A pharmacy partner |
| Last reviewed | 16 October 2026 |
Ordering from Indiana
ExaVeyra ships to licensed practices in all 50 states, Indiana included. Licensure for shipping into the state is held by the entities that ship: our 503A pharmacy partner holds nonresident pharmacy licenses in 33 jurisdictions, including Puerto Rico, and exosome material ships from a registered tissue bank licensed to ship to all 50 states and Puerto Rico. Your practice orders against its own professional license and NPI and needs no wholesale permit to purchase.
What your practice provides
- An active Indiana professional license in good standing, verifiable through the Indiana Professional Licensing Agency’s MyLicense eVerification portal.
- A valid NPI, which ExaVeyra verifies at account setup.
- A signed professional-use acknowledgment on file for exosome material.
- An Indiana sales tax registration and resale exemption documentation through the Department of Revenue if the practice is purchasing for resale rather than for use in its own operations.
How the state permits wholesale distribution
Indiana licenses wholesale distribution of legend drugs through the Board of Pharmacy, within the Professional Licensing Agency, and the same chapter licenses third-party logistics providers. The distinctive feature is accreditation: IC 25-26-14-14 conditions the wholesale license on accreditation from the National Association of Boards of Pharmacy, so an Indiana license carries a third-party audit behind it. The chapter also carries pedigree and surety bond requirements, and in-state and out-of-state distributors are licensed under the same chapter, with reciprocity available where the home state’s standards are comparable. The license sits with the distributor, not with the purchasing practice.
Ind. Code ch. 25-26-14; 856 Ind. Admin. Code art. 3 · Indiana Board of Pharmacy (Indiana Professional Licensing Agency)
Indiana regenerative-medicine law
Indiana has not enacted a statute specific to stem cell or regenerative therapies. Practice in this area is governed by the state's general medical practice and professional licensing rules, alongside federal law.
No Indiana statute addresses unapproved regenerative therapy in clinical practice. The state has no stem cell authorization law like Florida, Texas, or Georgia, no consumer disclosure law like California, and no documentation statute like Tennessee. Where Indiana’s statute books touch stem cells at all, it is around embryonic research limits and umbilical cord blood banking, neither of which conditions or authorizes a clinical service. Practice in this area is governed by the Medical Practice Act, the Nurse Practice Act, and the boards that administer them, alongside federal law, which is the only layer that reaches the products themselves.
How this applies to exosomes
Indiana has no stem cell statute, so there is no Indiana definition to read exosomes into or out of in the first place. The distinction still matters, because stem cell marketing and exosome marketing are routinely conflated: exosomes are acellular extracellular vesicles rather than cells, and even in the states that have enacted stem cell laws, those statutes are written around cells and tissues and do not reach acellular vesicles. In Indiana as everywhere, exosome products are governed by federal law, under which no exosome product has been approved by the FDA for administration to humans. ExaVeyra supplies Kimera material for topical aesthetic use by licensed practitioners, with full COA and lot documentation.
Who can handle product in a Indiana practice
The practical feature of Indiana is consolidation: the Medical Licensing Board, the State Board of Nursing, and the Board of Pharmacy all sit within the Indiana Professional Licensing Agency, and every license verifies through the single MyLicense eVerification portal. An APRN or PA working in an aesthetic or regenerative practice does so under a collaborative arrangement with a physician, so a physician-led structure with written delegation protocols is the configuration to plan around.
| Role | Scope under state law |
|---|---|
| MD / DO | Physicians licensed by the Medical Licensing Board of Indiana may perform medical acts within their scope and are the source of any delegation to staff who do not hold independent authority. The board administers physician licensure through the Indiana Professional Licensing Agency. |
| NP / APRN | Indiana advanced practice registered nurses operate in collaboration with a licensed practitioner under IC 25-23-1-19.4, and prescriptive authority under IC 25-23-1-19.5 requires a practice agreement with a collaborating physician, with renewal and audit provisions in the same chapter. Indiana is not a full practice authority state. |
| PA | Physician assistants practice under IC 25-27.5 within an agreement with a collaborating physician, in the scope that agreement establishes, administered through the Indiana Professional Licensing Agency. |
| RN | Registered nurses may perform delegated treatments within their license and under an order from a provider with authority to issue one, after that provider has evaluated the patient. An RN does not diagnose, prescribe, or independently select a treatment. |
Good faith examination
Indiana expects a patient evaluation by a provider with authority to conduct it, and an order, before a delegated treatment is administered. Because the expectation is set by board interpretation and the collaborative agreements themselves rather than a single statute, confirm current requirements with the Medical Licensing Board of Indiana and the Indiana State Board of Nursing.
Ownership and clinic licensing
Indiana does not codify a corporate practice of medicine prohibition in the way Texas, New York, or New Jersey do. Professional corporations and management services arrangements are the usual structures, and the doctrine survives mainly through older case law and board expectations rather than a bright-line statute. Because published summaries disagree on how far the doctrine reaches, treat ownership structure as a question for Indiana counsel rather than one a guide should answer with a rule.
Cold chain into Indiana
Shipments leave Florida frozen under validated temperature monitoring. A package in transit over a weekend waits in the carrier network, so practices in Indiana order around weekend and holiday closures.
| Metro | County | Notes |
|---|---|---|
| Indianapolis | Marion | Largest Indiana market, with broad aesthetic and clinical coverage. |
| Carmel | Hamilton | Dense north-metro med spa and concierge corridor. |
| Fishers | Hamilton | Fast-growing suburban market served alongside Carmel. |
| Fort Wayne | Allen | Northeast Indiana hub with a steady dermatology base. |
| Evansville | Vanderburgh | Southwest Indiana market serving the tri-state border. |
| South Bend | St. Joseph | North central market with academic medical presence. |
- Indiana orders of fifteen or more cold-chain units ship free nationwide; see the volume program for current thresholds.
- Every vial arrives with the manufacturer’s handling instructions and a Certificate of Analysis, and storage on arrival follows the COA and labeling rather than a general rule.
Wholesale exosome supply by city in Indiana
Each city page covers local receiving conditions, delivery disruptions and business license rules for Indiana practices in that area.
Practice types we supply in Indiana
Indiana licensing and verification
Medical Licensing Board of Indiana
Physician licensure, within the Indiana Professional Licensing Agency.
Indiana State Board of Nursing
RN, LPN, and APRN licensure, including prescriptive authority credentials.
Indiana Board of Pharmacy
Issues the wholesale drug distributor license under IC 25-26-14.
Indiana Department of Revenue
Sales tax registration and resale exemption documentation.
Indiana sourcing questions
- Does Indiana have a stem cell law?
- No. Indiana has no stem cell authorization law like Florida, Texas, or Georgia, no consumer disclosure law like California, and no documentation statute like Tennessee. Where its statute books touch stem cells at all, it is around embryonic research limits and cord blood banking, neither of which reaches clinical practice. Exosome products in Indiana are governed by federal law, under which no exosome product is FDA-approved for administration to humans.
- What is distinctive about Indiana wholesale drug licensing?
- Accreditation. IC 25-26-14-14 conditions the wholesale drug distributor license on accreditation from the National Association of Boards of Pharmacy, so every licensed distributor shipping legend drugs into Indiana carries a third-party audit behind the license. The chapter also licenses third-party logistics providers and carries pedigree and surety bond requirements. All of that sits on the distributor, not on the buying practice.
- Does my Indiana clinic need a wholesale distributor license to buy exosomes?
- No. The wholesale drug distributor license under IC 25-26-14 is held by the distributor shipping into Indiana, not by the practice buying. Your practice orders against its own professional license and NPI. Licensure for shipping into the state is held by the entities that ship: our 503A pharmacy partner for compounded preparations, and a registered tissue bank licensed to ship to all 50 states and Puerto Rico for exosome material.
- Can a nurse practitioner practice independently in Indiana?
- No. Indiana advanced practice registered nurses operate in collaboration with a licensed practitioner under IC 25-23-1-19.4, and prescriptive authority requires a practice agreement with a collaborating physician under IC 25-23-1-19.5. A physician-led structure with written delegation protocols is the configuration an Indiana aesthetic or regenerative practice plans around.
- Are exosome products FDA approved?
- No exosome product has been approved by the FDA for administration to humans, a position the FDA stated in its 2019 public safety notification on exosome products. ExaVeyra supplies Kimera material for topical aesthetic use by licensed practitioners, with a Certificate of Analysis and lot traceability on every vial.
- How long does cold-chain shipping take to Indiana?
- Ships from Florida by overnight shipping, and arrival can take one to three business days. All exosome shipments travel cold-chain with validated temperature monitoring. A shipment in transit over a weekend waits in the carrier network, so a practice that will be closed orders around the closure.
Sources
Last reviewed 16 October 2026 by ExaVeyra Sciences editorial team. Every claim above links to a primary source.
- Indiana Code, Title 25 (IC 25-26-14, wholesale legend drug distributors and third party logistics providers) (accessed 16 October 2026)
- Indiana Board of Pharmacy (Indiana PLA) (accessed 16 October 2026)
- Medical Licensing Board of Indiana (Indiana PLA) (accessed 16 October 2026)
- Indiana State Board of Nursing (Indiana PLA) (accessed 16 October 2026)
- Indiana PLA MyLicense eVerification portal (accessed 16 October 2026)
- Indiana Department of Revenue (accessed 16 October 2026)
- FDA Public Safety Notification on Exosome Products (accessed 16 October 2026)
Scientific literature
Peer-reviewed references, each with its study design and, for human studies, the number of participants, so a reader can judge the weight of a citation without opening it. None is a claim about any product.
- Welsh JA, Goberdhan DCI, O’Driscoll L, et al. Minimal information for studies of extracellular vesicles (MISEV2023): From basic to advanced approaches. Journal of Extracellular Vesicles, 2024. doi:10.1002/jev2.12404 PMID:38326288Consensus statementsupports: Supports the documentation standard this page describes: the field-consensus characterization measures, including particle counts and marker panels, that a COA-literate buyer looks for on an exosome Certificate of Analysis.
- Lener T, Gimona M, Aigner L, et al. Applying extracellular vesicles based therapeutics in clinical trials - an ISEV position paper. Journal of Extracellular Vesicles, 2015. doi:10.3402/jev.v4.30087 PMID:26725829Consensus statementsupports: Supports the page’s statement that extracellular vesicle based products remain investigational and that defined manufacturing and documentation, not state statute, is what separates characterized material from uncharacterized material.
- Ha DH, Kim HK, Lee J, et al. Mesenchymal Stem/Stromal Cell-Derived Exosomes for Immunomodulatory Therapeutics and Skin Regeneration. Cells, 2020. doi:10.3390/cells9051157 PMID:32392899Narrative reviewsupports: Supports the page’s description of MSC-derived exosomes as the source material class behind perinatal MSC-EV preparations, and of why source characterization matters to a purchasing practice.
These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease. There are no FDA-approved exosome products. Biomolecular signaling vesicle products distributed by ExaVeyra Sciences are supplied for topical aesthetic use by licensed practitioners and for laboratory and IND-authorized clinical research, and are not tissue products as defined by FDA guidelines.